Eli Lilly and Company
893 S Delaware St
Indianapolis
Indiana
46285
United States
About Eli Lilly and Company
Science has been our calling from the beginning. Colonel Eli Lilly founded the company in 1876 and charged employees to “take what you find here and make it better and better.” More than 147 years later, we remain committed to his vision through every aspect of our business and the people we serve, starting with discovering the best treatments for those who take our medicines and extending to health care professionals, employees and the communities in which we live. Moreover, you can also count on the team at Lilly to be incredibly civic-minded, supporting our communities through philanthropy, volunteerism, and a creative and innovative can-do spirit.
Karina found her fit at Lilly through our summer internship program. She is now hoping to inspire more Latinx students to make changes in the STEM field just as her mentor did for her. Visit careers.lilly.com/LRL to find open roles in Lilly’s research labs. #WeAreLilly
3430 articles about Eli Lilly and Company
-
DP Technology Announces Nomination of Development Candidate, a Potential Best-in-Class Kv1.3 Inhibitor for Immunological Diseases Including IBD and AD
1/30/2024
DP Technology, an "AI for Science" new paradigm-driven company, announced the nomination of DPT0218, a novel small molecule targeting Kv1.3, as a preclinical candidate compound for the treatment of various autoimmune diseases, including Inflammatory Bowel Disease and Atopic Dermatitis.
-
Johna Norton to Retire as Lilly Executive Vice President of Global Quality
1/25/2024
Eli Lilly and Company announced that Johna Norton, executive vice president of Global Quality, will be retiring after 34 years of service with the company, effective July 31, 2024.
-
In a Phase I/II trial, an 11-year-old boy gradually regained hearing—eventually reaching normal range for some frequencies at 30 days—following treatment with Eli Lilly’s dual adeno-associated viral vector-delivered gene therapy.
-
Positive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss to be Presented at the Association for Research in Otolaryngology 2024 MidWinter Meeting
1/23/2024
Akouos, Inc., a wholly owned subsidiary of Eli Lilly and Company (NYSE: LLY), today announced positive initial clinical results from the Phase 1/2 AK-OTOF-101 study, which demonstrated pharmacologic hearing restoration within 30 days of AK-OTOF administration in the first participant, an individual with a decade-plus history of profound hearing loss.
-
Lilly Confirms Date and Conference Call for Fourth-Quarter 2023 Financial Results and 2024 Financial Guidance
1/23/2024
Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2023 financial results and 2024 financial guidance on Feb. 6, 2024.
-
The multimillion-dollar collaboration will develop small molecule drugs against undisclosed targets.
-
Isomorphic Labs Announces Strategic Multi-Target Research Collaboration With Lilly
1/7/2024
Isomorphic Labs, a digital biology company with a mission to redefine drug discovery using the power of artificial intelligence, announced that it has entered into a strategic research collaboration with Eli Lilly and Company.
-
Eli Lilly on Thursday announced the rollout of a new digital healthcare platform to streamline consumer access to its weight-loss drug Zepbound and other medications.
-
The regulator is launching an investigation of Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound and other GLP-1 receptor agonists following patient reports of suicidal ideation, alopecia and aspiration.
-
Lilly Launches End-to-End Digital Healthcare Experience through LillyDirect™
1/4/2024
Eli Lilly and Company (NYSE: LLY) today announced LillyDirect ™, a new digital healthcare experience for patients in the U.S. living with obesity, migraine and diabetes.
-
The Max Foundation Announces Agreement with Lilly to Provide Access to Verzenio® (abemaciclib) for the Treatment of Advanced Breast Cancer in Kenya
1/4/2024
The Max Foundation (Max), a leading global nonprofit organization dedicated to accelerating health equity by delivering medication, technology, and supportive services to patients globally today announced Eli Lilly and Company will provide free of charge access to Verzenio® (abemaciclib) for the treatment of HR-positive, HER2-negative ABC for patients in Kenya.
-
Sitryx announces collaboration partner Lilly has commenced a Phase 1 study of SIT-011 for chronic autoimmune and inflammatory diseases
1/4/2024
Sitryx Therapeutics announces that Eli Lilly & Company has commenced a Phase 1 first-in-human study of SIT-011, a post-translational modification modulator program for chronic autoimmune and inflammatory diseases.
-
Lilly to Participate in J.P. Morgan Healthcare Conference - January 2, 2024
1/2/2024
Eli Lilly and Company (NYSE: LLY) will attend the 42nd Annual J.P. Morgan Healthcare Conference, Jan. 8-11 , 2024.
-
Lilly Completes Acquisition of POINT Biopharma
12/27/2023
Eli Lilly and Company announced the successful completion of its acquisition of POINT Biopharma Global Inc., a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer.
-
Eli Lilly has signed a multi-year contract with animal genomics biotech Fauna Bio to use its artificial intelligence platform to discover drug targets for obesity in a deal worth nearly half a billion dollars.
-
Fauna Bio Announces Strategic Collaboration with Lilly to Discover Novel Obesity Targets Using Convergence™ AI Platform
12/21/2023
Fauna Bio today announced a multi-year agreement with Eli Lilly and Company to apply Fauna's Convergence™ artificial intelligence (AI) platform to support preclinical drug discovery efforts in obesity.
-
Point and Lantheus’s Radioligand Drug Shows Effectiveness, but Not Enough for Wall Street
12/18/2023
While the candidate was effective in Phase III results, Point’s stock price fell following the announcement. -
Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 22, 2023
12/18/2023
Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT Biopharma Global Inc. (NASDAQ: PNT), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding.
-
Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine Medicines
12/18/2023
Organon becomes the sole distributor and promoter of Emgality ® (galcanezumab) and RAYVOW ™ (lasmiditan) in Europe, building on strong commercial expertise in central nervous system disorders.
-
Updated Data from the BRUIN Phase 1/2 Study of Pirtobrutinib in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Presented at the 2023 ASH Annual Meeting
12/12/2023
Eli Lilly and Company announced updated clinical data from the international Phase 1/2 BRUIN trial of pirtobrutinib, a non-covalent Bruton's tyrosine kinase inhibitor, in adult patients with a range of B-cell malignancies.